4.8 Review

Exposing the exposures responsible for type 2 diabetes and obesity

期刊

SCIENCE
卷 354, 期 6308, 页码 69-73

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaf5094

关键词

-

资金

  1. Wellcome Trust [098381]
  2. European Commission [HEALTH-F4-2007-201413, CoG-2015_681742_NASCENT, IMI_JU_2010_DIRECT, IMI_JU_2016_RHAPSODY]
  3. Medical Research Council [MR/L020149/1, MR/M004422/1]
  4. National Institutes of Health [DK098032, DK105535]
  5. Swedish Research Council (Distinguished Young Researchers Award in Medicine)
  6. Swedish Heart-Lung Foundation
  7. Swedish Diabetes Association
  8. European Foundation for the Study of Diabetes
  9. Novo Nordisk Foundation
  10. Pfizer
  11. Roche
  12. Novo Nordisk
  13. Eli Lilly
  14. AstraZeneca
  15. Sanofi Aventis
  16. Johnson Johnson
  17. Servier
  18. Takeda
  19. Boehringer Ingelheim
  20. European Foundation for the Study of Diabetes [MSD 2015_2] Funding Source: researchfish
  21. Medical Research Council [MR/L020149/1, MR/M004422/1] Funding Source: researchfish
  22. MRC [MR/M004422/1, MR/L020149/1] Funding Source: UKRI

向作者/读者索取更多资源

The rising prevalences of type 2 diabetes and obesity constitutemajor threats to human health globally. Powerful social and economic factors influence the distribution of these diseases among and within populations. These factors act on a substrate of individual predisposition derived from the composite effects of inherited DNA variation and a range of environmental exposures experienced throughout the life course. Although Western lifestyle represents a convenient catch-all culprit for such exposures, effective treatment and prevention will be informed by characterization of the most critical, causal environmental factors. In this Review, we examine how burgeoning understanding of the genetic basis of type 2 diabetes and obesity can highlight nongenetic exposures that drive development of these conditions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据